BioCentury
ARTICLE | Clinical News

Gemesis bercaplermin regulatory update

January 9, 2012 8:00 AM UTC

BioMimetic said GEM 21S received CE Mark approval in the EU to treat osseous defects resulting from tooth extraction and trauma and for use in compromised patients where poor healing may occur. The ap...